Top segments and regional performance

Last year, the company generated ‪6.50 M‬ USD, the most of which — ‪6.50 M‬ USD — came from its top-performing segment, Targeted Radiopharmaceuticals, compared to ‪1.49 M‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪6.50 M‬ USD last year, with ‪1.49 M‬ USD the year before.